Somatropin With Or Without Prescription At Silver Med Shop
Somatropin is a polypeptide hormone of recombinant DNA origin. Humatrope is synthesized in a strain of Escherichia coli that the addition of the gene has changed for human GH. The peptide comprises 191 amino acid residues and has a molecular weight of about 22,125 Daltons. The amino acid sequence of the peptide is identical to that of human GH of pituitary origin.
before and after hgh, buy somatropin australia, Genotropin, gh, gh gut, grow taller, growth hormone, growth hormone effects, growth hormone injection, growth hormone pills, growth hormone side effects, growth hormone supplement, growth hormone supplements, growth hormones, growth pills, hgh australia, hgh before and after, hgh before and after face, hgh benefits, hgh cycle, hgh dosage, hgh for sale, hgh gut, hgh hormone, HGH Injections, hgh results, hgh side effects, hormone injections, human growth hormone, human growth hormone benefits, human growth hormone bodybuilding, human growth hormone buy, human growth hormone canada, human growth hormone for sale, human growth hormone injections, human growth hormone side effects, Humatrope, hygetropin, Norditropin, novartis, novartis australia, nubest tall australia, side effects of hgh, somatotropin, Somatropin, somatropin australia, somatropin hgh, what is hgh, what is human growth hormone
Humatrope is a sterile, white, lyophilized powder intended for subcutaneous or intramuscular administration after reconstitution to its liquid form. Humatrope is a highly purified preparation. Phosphoric acid and/or sodium hydroxide may have been added to adjust the ph. Reconstituted solutions have a pH of approximately 7.5. This product is oxygen sensitive. somatropin for sale
Each vial of Humatrope contains 5 mg somatropin (15 IU or 225 nanomoles); 25 mg mannitol; 5 mg glycine; and 1.13 mg dibasic sodium phosphate. They supplied each vial in a combination package with an accompanying 5-mL vial of diluting solution (diluent). The diluent contains water for injection with 0.3% metacresol as a preservative and 1.7% glycerin.
Growth Hormone Deficiency
Humatrope is showed to treat pediatric patients who have growth failure because of inadequate secretion of endogenous growth hormone (GH).
Short Stature Associated with Turner Syndrome
Humatrope is showed to treat short stature associated with Turner syndrome .
Idiopathic Short Stature
Humatrope is indicated to treat idiopathic short stature, also called non-GH-deficient short stature, defined by height SDS ≤ -2.25 and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients for whom diagnostic evaluation excludes other causes of short stature that should be observed or treated by other means SDS = standard deviation scores.
Humatrope has showed to treat short stature or growth failure in children with short stature homeobox-containing gene (SHOX) deficiency
Small for Gestational Age
Humatrope has showed to treat growth failure in children born small for gestational age (SGA) who cannot show catch-up growth by age two to four years
Humatrope is shown for the replacement of endogenous GH in adults with GH deficiency who meet either of the following two criteria
Patients who have GH deficiency, either alone or associated with multiple hormone deficiencies (hypopituitarism), because of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or
Patients who were GH deficient during childhood because of congenital, genetic, acquired, or idiopathic causes.
We should reevaluate patients who were treated with somatropin for GH deficiency in childhood and whose epiphyses are closed before continuation of somatropin therapy at the reduced dose level recommended for GH-deficient adults. According to current standards, confirmation of the diagnosis of adult GH deficiency in both groups involves an appropriate GH provocative test with two exceptions: (1) patients with multiple other pituitary hormone deficiencies because of organic dis.
DOSAGE AND ADMINISTRATION somatropin
For subcutaneous injection.
Therapy with Humatrope should be supervised by a physician who is experienced in the diagnosis and management of pediatric patients with short stature associated with GH deficiency, Turner syndrome, idiopathic short stature, SHOX deficiency, small for gestational age birth, or adult patients with either childhood-onset or adult-onset GH deficiency.
Each 5-mg vial of Humatrope should be reconstituted with 1.5 to 5 mL of Diluent for Humatrope. The diluent should be injected into the vial of Humatrope by aiming the stream of liquid gently against the vial wall. Following reconstitution, they should swirl the vial with a GENTLE rotary motion until it completely dissolved the contents. DO NOT SHAKE. The resulting solution should be clear. If the solution is cloudy or contains particulate matter, the contents MUST NOT be injected.
If sensitivity to the diluent should occur, the vials may be reconstituted with Bacteriostatic Water for Injection (Benzyl Alcohol preserved), USP or Sterile Water for Injection, USP. When Humatrope is reconstituted with Bacteriostatic Water for Injection, USP, the solution should be kept refrigerated at 36° to 46°F (2° to 8°C) and used within 14 days. It is important to note that benzyl alcohol used as a preservative in Bacteriostatic Water has been associated with toxicity in newborns. Therefore, Bacteriostatic Water for Injection must not be used to reconstitute Humatrope for a newborn infant. When Humatrope is to be administered to a newborn infant, it should be reconstituted with the diluent provided or, if the infant is sensitive to the diluent, Sterile Water for Injection, USP. When reconstituted with Sterile Water for Injection the solution should be kept refrigerated at 36° to 46°F (2° to 8°C) and used within 24 hours.
We have designed the Humatrope cartridge for use only with the Humatrope injection device. Each cartridge of Humatrope should be reconstituted using only the diluent syringe that accompanies the cartridge and should not be reconstituted with the Diluent for Humatrope provided with Humatrope vials. The reconstituted solution should be clear. If the solution is cloudy or contains particulate matter, the contents MUST NOT be injected. Humatrope cartridges should not be used if the patient is allergic to metacresol or glycerin.
The somatropin concentrations for the reconstituted Humatrope cartridges are:
6 mg cartridge (gold) 2.08 mg/mL
12 mg cartridge (teal) 4.17 mg/mL
24 mg cartridge (purple) 8.33 mg/mL
[See HOW SUPPLIED and Information for the Patient for comprehensive directions on Humatrope cartridge reconstitution].
General Administration Guidelines
For all indications, we should follow the following general principles for administration:
- When using the Humatrope vial, we should wipe the septum of the vial with an alcoholic antiseptic solution before and after each injection to prevent contamination of the contents by repeated needle insertions. Sterile disposable syringes and needles should be used. The volume of the syringe should be small enough so that we can withdraw the prescribed dose from the vial with reasonable accuracy.
- When using the Humatrope cartridge we should use a sterile disposable needle for each injection.
- Humatrope should be administered by subcutaneous injection with a regular rotation of injection sites to avoid lipoatrophy.
- For pediatric patients, the calculated weekly Humatrope dosage should be divided into equal doses given either 6 or 7 days per week.
- For adult patients, we should administer the prescribed dose daily.
Dosing For Pediatric Patients
The Humatrope dosage and administration schedule should be individualized for each patient based on the growth response. Failure to increase height velocity, particularly during the first year of treatment, should prompt a close assessment of compliance and evaluation of other causes of poor growth, such as hypothyroidism, under-nutrition, advanced bone age, and antibodies to recombinant human growth hormone. Response to somatropin treatment decreases with time. Somatropin treatment for stimulation of linear growth should be discontinued once epiphyseal fusion has occurred. somatropin for sale
The recommended weekly dosages in milligrams (mg) per kilogram (kg) of body weight for pediatric patients are:
Growth hormone deficiency 0.026 to 0.043 mg/kg/day (0.18 to 0.30 mg/kg/week)
Turner syndrome up to 0.054 mg/kg/day (0.375 mg/kg/week)
Idiopathic short stature up to 0.053 mg/kg/day (0.37 mg/kg/week)
SHOX deficiency 0.050 mg/kg/day (0.35 mg/kg/week)
Small for gestational age up to 0.067 mg/kg/day (0.47 mg/kg/week)a
Recent literature has recommended initial treatment with larger doses of somatropin (e.g., 0.067 mg/kg/day), especially in very short children (i.e., height SDS < –3), and/or older pubertal children, and that a reduction in dosage (e.g., gradually towards 0.033 mg/kg/day) should be considered if substantial catch-up growth is observed during the first few years of therapy. In younger SGA children (e.g., approximately < 4 years) (who respond the best) with less severe short stature (i.e., baseline height SDS values between -2 and -3), consideration should be given to starting treatment at a lower dose (e.g., 0.033 mg/kg/day), and titrating the dose as needed. In all children, clinicians should carefully monitor the growth response, and adjust the somatropin dose as necessary.
Dosing For Patients With Adult Growth Hormone Deficiency somatropin for sale.
Either of two approaches to Humatrope dosing may be followed: a non-weight-based regimen or a weight-based regimen.
based on published consensus guidelines, a starting dose of approximately 0.2 mg/day (range, 0.15-0.30 mg/day) may be used without consideration of body weight. We can increase gradually this dose every 1-2 months by increments of approximately 0.1-0.2 mg/day, according to individual patient requirements based on the clinical response and serum insulin-like growth factor I (IGF-I) concentrations. We should decrease the dose as necessary because of adverse events and/or serum IGF-I concentrations above the age-and gender-specific normal range. Maintenance dosages differ from person to person, and between male and female patients. somatropin for sale
based on the dosing regimen used in the original adult GH deficiency registration trials, the recommended dosage at the start of treatment is no over 0.006 mg/kg (6 μg/kg) daily. We may increase the dose according to individual patient requirements to a maximum of 0.0125 mg/kg (12.5 μg/kg) daily. Clinical response, side effects, and determination of age-and gender-adjusted serum IGF-I concentrations should be used as guidance in dose titration. somatropin for sale
We should consider a lower starting dose and smaller dose increments for older patients, who are more prone to the adverse effects of somatropin than younger individuals. In addition, obese individuals are more likely to manifest adverse effects when treated with a weight-based regimen. Estrogen-replete women may need higher doses than men. Oral estrogen administration may increase the dose requirements in women.
SIDE EFFECTS of somatropin
Most Serious And/or Most Frequently Observed Adverse Reactions
This list presents the most serious and/or most frequently observed adverse reactions during treatment with somatropin (including events observed in patients who received brands of somatropin other than Humatrope):
- a Sudden death in pediatric patients with Prader-Willi syndrome who had risk factors including severe obesity, history of upper airway obstruction or sleep apnea and unidentified respiratory infection [see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS]
- intracranial tumors, in particular meningiomas, in teenagers/young adults treated with radiation to the head for a first neoplasm who subsequently receive somatropin [see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS]
- pancreatitis [see WARNINGS AND PRECAUTIONS]
- a,glucose intolerance including impaired glucose tolerance/impaired fasting glucose and overt diabetes mellitus [see WARNINGS AND PRECAUTIONS]
- Intra cranial hypertension [see WARNINGS AND PRECAUTIONS]
- a significant diabetic retinopathy [see CONTRAINDICATIONS]
- slipped capital femoral epiphysis in pediatric patients [see WARNINGS AND PRECAUTIONS]
- progression of preexisting scoliosis in pediatric patients [see WARNINGS AND PRECAUTIONS]
- by fluid retention manifested by edema, arthralgia, myalgia, nerve compression syndromes including carpal tunnel syndrome/paresthesia’s [see WARNINGS AND PRECAUTIONS]
- unmasking of latent central hypothyroidism [see WARNINGS AND PRECAUTIONS]
- injection site reactions/rashes and lipoatrophy (as well as rare generalized hypersensitivity reactions) [see WARNINGS AND PRECA